
https://www.science.org/content/blog-post/lilly-s-open-screening-program-update
# Lilly's Open Screening Program: An Update (September 2011)

## 1. SUMMARY  
The 2011 post reports on Eli Lilly’s “Open Screening” initiative, launched a few years earlier to let external researchers submit compounds for testing in Lilly’s proprietary phenotypic and, more recently, target‑based assays. Submissions are filtered through a fire‑walled computational check that removes toxic or non‑novel structures; the company retains “first rights of negotiated access” to any promising hits. By the time of the report, 252 external partners (174 academic groups and 78 small companies) had submitted ~42 000 compounds, of which ~40 % were rejected for lack of novelty. Only 115 structures were requested for disclosure, 97 were shared with Lilly, and 13 were retained for further work, leading to two signed collaborations and several negotiations in progress. The author notes that the program appears successful enough to be expanded to additional assays and hopes other firms will follow suit.

## 2. HISTORY  
**Continuation and evolution (2011‑2015)**  
- Lilly kept the Open Innovation portal (openinnovation.lilly.com) active through the mid‑2010s, adding more assay types (e.g., kinase panels, cell‑based disease models) and a “Challenge” format that solicited ideas rather than raw compounds.  
- The program generated a modest number of follow‑on projects, most of which remained at the hit‑validation or early‑lead stage. Public disclosures (press releases, conference abstracts) mention collaborations on anti‑infective and metabolic targets, but none progressed to IND filing within the public record.

**Limited commercial impact (2015‑2020)**  
- No drug candidate that can be traced directly to the Open Screening pipeline received FDA approval as of 2024. The few leads that advanced to pre‑clinical testing were either deprioritized in favor of internally generated chemistry or merged into broader Lilly discovery programs, making attribution difficult.  
- By 2017 Lilly’s public communications shifted from “open screening” to a broader “Open Innovation” narrative emphasizing crowdsourced ideas, data sharing, and partnership models (e.g., the “Lilly‑M4” partnership with academic consortia). The specific compound‑submission portal received less visibility and appears to have been de‑prioritized, with the web address eventually redirecting to a generic partnership page.

**Industry context**  
- Other large pharma (e.g., GSK, Pfizer, Novartis) launched similar open‑innovation portals in the early 2010s, but most experienced the same pattern: a burst of early collaborations followed by a retreat to internal discovery pipelines.  
- The NIH’s Molecular Libraries Program, a public counterpart to corporate open screening, was discontinued in 2015, reflecting a broader reassessment of the cost‑effectiveness of large‑scale open compound screening.

**Current status (2024)**  
- Lilly still lists “Open Innovation” on its corporate site, but the specific “open screening” submission portal is no longer advertised. The company now focuses on challenge‑based collaborations, data‑sharing platforms, and strategic alliances rather than bulk compound‑screening from external sources.

## 3. PREDICTIONS  
| Prediction made in the 2011 article (or implied) | What actually happened |
|---|---|
| **More companies will adopt the open‑screening model** | A few did (GSK, Pfizer, Novartis) but the model never became mainstream; most firms kept proprietary screening. |
| **Lilly will expand the program to additional assays** | Lilly added a handful of target‑based panels and later incorporated the portal into a broader “Open Innovation” suite, but the expansion was modest and later de‑emphasized. |
| **The screened hits will lead to clinical candidates** | No FDA‑approved drugs can be traced back to the open‑screening hits; most leads stalled at early discovery or were folded into internal programs. |
| **External partners (academia & small companies) will find the MTA acceptable and collaborate readily** | Small companies were generally receptive; academic groups remained cautious, and the MTA remained a barrier for many collaborations, limiting uptake. |
| **The initiative will be seen as a success and inspire similar programs** | The initiative was viewed as a proof‑of‑concept rather than a commercial success; it inspired other “open‑innovation” pilots but not a lasting industry shift. |

## 4. INTEREST  
**Rating: 6/10**  
The article is a useful snapshot of an early‑stage open‑innovation experiment by a major pharma company, offering concrete metrics (partner count, compound numbers) that are rare in industry reporting. Its long‑term relevance is limited because the program did not produce breakthrough drugs, but it illustrates the challenges of open screening that continue to inform partnership strategies today.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110914-lilly-s-open-screening-program-update.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_